Sponsor pipeline

Cerenome clinical trial pipeline

5 active trials 4 recruiting 1 disease areas 6 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days

2026-09-10

NCT07061626 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in… · Phase 1

2026-09-10

NCT07098806 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for… · Phase 1/2

Phase 1		3
Phase 1/2		2

NCT ID	Title	Condition	Status	Updated
Phase 1/2
NCT07098806	Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for…	Leptomeningeal Metastasis	Recruiting	2026-09-09
NCT01906385	Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma…	Glioma	Recruiting	2025-03-26
Phase 1
NCT07061626	Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in…	Ependymoma	Recruiting	2026-09-11
NCT05460507	Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who…	Glioma	Recruiting	2025-03-30
NCT05034497	Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases	Leptomeningeal Metastasis	Active, Not Recruiting	2025-03-26

Get alerts when Cerenome's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.